Literature DB >> 1281317

In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription.

B Bordier1, C Hélène, P J Barr, S Litvak, L Sarih-Cottin.   

Abstract

The molecular events involved in antisense-mediated inhibition of retroviral transcription were studied by analyzing the in vitro effect of antisense oligodeoxynucleotides on reverse transcription by Human Immunodeficiency Virus type 1 (HIV-1) reverse transcriptase (RT). Oligonucleotides have been designed to be complementary to three targets located in the 5' region of the HIV-1 RNA genome: the transactivating response element (TAR), the U5 region and a sequence contiguous to the primer binding site (PrePBS). Antisense oligodeoxynucleotides were used with their 3'-OH end either free or blocked by a dideoxynucleotide in order to avoid cDNA synthesis. Experiments with two recombinant forms of HIV RT, carrying or not RNase H activity, showed that antisense oligonucleotides can arrest reverse transcription by an RNase H-independent mechanism. The AntiTAR oligonucleotide did not affect reverse transcription. In contrast, the AntiU5 and AntiPrePBS oligonucleotides led to an efficient inhibition of both forms of HIV RT. In the case of the AntiU5, the inhibition obtained in the absence of the RNase H activity indicates that this effect can be related to features of the RNA secondary structure. The AntiPrePBS oligonucleotide did bind to its target only in the presence of PBS primer. Use of shifted oligonucleotides showed that the AntiPrePBS inhibitory effect depends on a cooperative annealing with the AntiPBS primer on the template.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281317      PMCID: PMC334466          DOI: 10.1093/nar/20.22.5999

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  31 in total

Review 1.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids.

Authors:  C Hélène; J J Toulmé
Journal:  Biochim Biophys Acta       Date:  1990-06-21

2.  Blockage of AMV reverse transcriptase by antisense oligodeoxynucleotides.

Authors:  N Loreau; C Boiziau; P Verspieren; D Shire; J J Toulmé
Journal:  FEBS Lett       Date:  1990-11-12       Impact factor: 4.124

3.  Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).

Authors:  B Bordier; L Tarrago-Litvak; M L Sallafranque-Andreola; D Robert; D Tharaud; M Fournier; P J Barr; S Litvak; L Sarih-Cottin
Journal:  Nucleic Acids Res       Date:  1990-02-11       Impact factor: 16.971

4.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  A detailed model of reverse transcription and tests of crucial aspects.

Authors:  E Gilboa; S W Mitra; S Goff; D Baltimore
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

6.  Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates.

Authors:  C H Agris; K R Blake; P S Miller; M P Reddy; P O Ts'o
Journal:  Biochemistry       Date:  1986-10-07       Impact factor: 3.162

7.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Characterization of the human immunodeficiency virus type-1 reverse transcriptase enzyme produced in yeast.

Authors:  I C Bathurst; L K Moen; M A Lujan; H L Gibson; P H Feucht; S Pichuantes; C S Craik; D V Santi; P J Barr
Journal:  Biochem Biophys Res Commun       Date:  1990-09-14       Impact factor: 3.575

9.  Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.

Authors:  C Boiziau; N T Thuong; J J Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more
  14 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  A macrocyclic bis-acridine shifts the equilibrium from duplexes towards DNA hairpins.

Authors:  A Slama-Schwok; F Peronnet; E Hantz-Brachet; E Taillandier; M P Teulade-Fichou; J P Vigneron; M Best-Belpomme; J M Lehn
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

4.  Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA.

Authors:  U Koppelhus; V Zachar; P E Nielsen; X Liu; J Eugen-Olsen; P Ebbesen
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

Review 5.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

6.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

7.  The binding of an antisense oligonucleotide to a hairpin structure via triplex formation inhibits chemical and biological reactions.

Authors:  E Brossalina; E Pascolo; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1993-12-11       Impact factor: 16.971

8.  Deoxyribonucleotide-containing RNAs: a novel class of templates for HIV-1 reverse transcriptase.

Authors:  S O Gudima; E G Kazantseva; D A Kostyuk; I L Shchaveleva; O I Grishchenko; L V Memelova; S N Kochetkov
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

9.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

10.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.